* Singular Genomics Systems Inc OMIC.OQ OMIC.O is
expected
to show a fall in quarterly revenue when it reports results on
March 18 for the period ending December 31 2023
* The San Diego California-based company is expected to
report a
4.4% decrease in revenue to $731.33 thousand from $765 thousand
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Singular Genomics
Systems Inc
is for a loss of 34 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Singular
Genomics
Systems Inc is $0.63, above its last closing price of $0.50.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.38 -0.38 -0.31 Beat 18.4
Jun. 30 2023 -0.39 -0.37 -0.35 Beat 5.4
Mar. 31 2023 -0.35 -0.35 -0.33 Beat 6.8
Dec. 31 2022 -0.41 -0.43 -0.29 Beat 31.9
Sep. -0.41 -0.41 -0.33 Beat 20.3
30 2022
Jun. 30 2022 -0.39 -0.38 -0.34 Beat 11.5
Mar. 31 2022 -0.33 -0.33 -0.31 Beat 7
Dec. 31 2021 -0.31 -0.31 -0.27 Beat 12.3
This summary was machine generated March 15 at 20:55 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)